Back to top
more

CorMedix (CRMD)

(Delayed Data from NSDQ)

$11.69 USD

11.69
3,106,447

+0.57 (5.13%)

Updated Sep 18, 2025 04:00 PM ET

After-Market: $11.65 -0.04 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adagene Inc. Sponsored ADR (ADAG) and CorMedix (CRMD) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Why CorMedix (CRMD) Might be Well Poised for a Surge

by Zacks Equity Research

CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

by Zacks Equity Research

KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.

Zacks Equity Research

Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.

Ethan Feller headshot

Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?

by Ethan Feller

Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts

Zacks Equity Research

SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus

by Zacks Equity Research

Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.

Zacks Equity Research

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

IMVT reports a narrower Q1 loss, as spotlight remains on IMVT-1402's broad clinical potential across multiple indications.

Zacks Equity Research

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

by Zacks Equity Research

XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.

Zacks Equity Research

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26

by Zacks Equity Research

Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.

Zacks Equity Research

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

by Zacks Equity Research

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Zacks Equity Research

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

by Zacks Equity Research

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

Zacks Equity Research

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

by Zacks Equity Research

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

Zacks Equity Research

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Zacks Equity Research

NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View

by Zacks Equity Research

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Zacks Equity Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.

Zacks Equity Research

Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

by Zacks Equity Research

CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.

Zacks Equity Research

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

by Zacks Equity Research

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks Equity Research

CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

by Zacks Equity Research

ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.

Zacks Equity Research

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

by Zacks Equity Research

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

Zacks Equity Research

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Zacks Equity Research

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

by Zacks Equity Research

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Zacks Equity Research

Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut

by Zacks Equity Research

PRGO tops Q2 EPS but misses revenue; trims 2025 sales outlook, sending shares down in pre-market.